Green Cross/Oxford Biomedica Alliance Eyes Novel NK Cell Therapies
This article was originally published in PharmAsia News
Green Cross LabCell, a subsidiary of South Korean biopharma group Green Cross Holdings, has tied up with Oxford BioMedica to develop novel gene-modified natural killer cell-based therapeutics for cancer and other life-threatening diseases. The partnership brings together the UK firm’s gene delivery platform and LabCell’s proprietary manufacturing technology for activated NK cells.
Register for our free email digests: